Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

3,195.36
+63.672.03%
Number of Gainers:3
Number of Losers:2
Number of Flat:- -
PE:- -
High:3,195.62
Open:3,132.42
Low:3,115.49
Close:3,131.69
Volume:9.47M
Turnover:340.99M
Market Cap:53.23B
Float Cap:50.45B

Loading ...

Xtant Medical Q3 Revenue Misses Estimates; Withdraws Guidance

Reuters
·
1 hour ago

Dare Bioscience Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview

Reuters
·
Nov 14

Biomedical Firm Femasys' Q3 Revenue Slumps on Lower International Orders

Reuters
·
Nov 14

Evofem Swings to Q3 Net Income of $1 Million

Reuters
·
Nov 14

Femasys Inc Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 14

Press Release: Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update

Dow Jones
·
Nov 14

Alkermes Exclusivity Extension for Lybalvi Offsets Alixorexton Pricing Adjustment, RBC Says

MT Newswires Live
·
Nov 14

Teva’s Innovation-Led Pipeline and Expanding Portfolio Support a $54 Price Target

TIPRANKS
·
Nov 13

Does First R And D Day Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Nov 13

Daré Bioscience Holds Special Stockholder Meeting

Reuters
·
Nov 12

Teva price target raised to $56 from $44 at Piper Sandler

TIPRANKS
·
Nov 12

Teva (TEVA) Stock Looks Undervalued Against Its Cash Flow Outlook

Simply Wall St.
·
Nov 12

MannKind Participates in UBS and Jefferies Investor Conferences

Reuters
·
Nov 10

Femasys Inc Expected to Post a Loss of 52 Cents a Share - Earnings Preview

Reuters
·
Nov 10

Teva Pharmaceutical Industries (TEVA) Following Guidance Lift And Samsung Bioepis Deal Is It Fully Valued

Simply Wall St.
·
Nov 10

Daré Bioscience Releases Next Episode in “CEO Corner” Video Series

GlobeNewswire
·
Nov 09

Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026

GlobeNewswire
·
Nov 09

Dare Bioscience Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview

Reuters
·
Nov 09

MannKind Likely Offering Favorable Demand Trends, RBC Says

MT Newswires Live
·
Nov 07

MannKind’s Growth Prospects and Royalty Strength Drive a Price-Target Increase to $10

TIPRANKS
·
Nov 06